|
注册号: Registration number: |
ChiCTR2300070807 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-19 17:16:47 |
|
注册时间: Date of Registration: |
2023-04-24 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
悦康通®银杏叶提取物注射液治疗急性原发性主观性耳鸣的多中心、前瞻性、安全性和有效性的临床研究 |
|
Public title: |
A multi-center, prospective clinical study for the safety and efficacy of Yuekangtong (extract of ginkgo biloba leaves) Injection in the treatment of acute primary subjective tinnitus |
|
注册题目简写: |
悦康通治疗耳鸣真实世界临床研究 |
|
English Acronym: |
Yuekangtong Real-world clinical study on tinnitus treatment |
|
研究课题的正式科学名称: |
悦康通银杏叶提取物注射液治疗急性原发性主观性耳鸣疗效评价的多中心、前瞻性、真实世界临床研究 |
|
Scientific title: |
A multi-center, prospective, real-world clincal study for the therapeutic efficacy of Yuekangtong extract of ginkgo biloba leaves injection in the treatment of acute primary subjective tinnitus |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨磊 |
研究负责人: |
韩德民;黄志刚;李永新 |
|
Applicant: |
Lei Yang |
Study leader: |
Han Demin; Huang Zhigang; Li Yongxin |
|
申请注册联系人电话: Applicant telephone: |
+86 137 1684 1049 |
研究负责人电话:
Study leader's |
+86 10 5826 9911 |
|
申请注册联系人传真 : Applicant Fax: |
+86 10 6787 3085 |
研究负责人传真: Study leader's fax: |
|
|
申请注册联系人电子邮件: Applicant E-mail: |
yanglei1020@126.com |
研究负责人电子邮件: Study leader's E-mail: |
entlyx@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市北京经济技术开发区宏达中路6号 |
研究负责人通讯地址: |
北京市东城区东交民巷1号 |
|
Applicant address: |
6 middle Hongda Road, Beijing Economic Technological Development Area, Beijing, China |
Study leader's address: |
1 Dongjiaomin Lane, Dongcheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
悦康药业集团股份有限公司 |
||
|
Applicant's institution: |
Youcare Pharmaceutical Group Co., Ltd |
||
|
研究负责人所在单位: |
首都医科大学附属北京同仁医院 |
||
|
Affiliation of the Leader: |
Beijing Tongren Hospital, CMU |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
TREC2021-110.A2 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京同仁医院伦理委员会 |
||
|
Name of the ethic committee: |
IRB of Beijing Tongren Hospital, CMU |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-03 00:00:00 | ||
|
伦理委员会联系人: |
邹岩 |
||
|
Contact Name of the ethic committee: |
Yan Zou |
||
|
伦理委员会联系地址: |
北京市东城区东交民巷1号西区门诊楼3楼 |
||
|
Contact Address of the ethic committee: |
3rd Floor, West Clinic Building, 1 Dongjiaomin Lane, Dongcheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5826 8422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
首都医科大学附属北京同仁医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Tongren Hospital Affiliated to Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市东城区东交民巷1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
1 Dongjiaomin Lane, Dongcheng District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
悦康药业集团股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Youcare Pharmaceutical Group Co., Ltd |
||||||||||||||||||||||
|
研究疾病: |
急性原发性主观性耳鸣 |
||||||||||||||||||||||
|
Target disease: |
Acute primary subjective tinnitus |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
评价悦康通®银杏叶提取物注射液治疗急性原发性主观性耳鸣的安全性和有效性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Evaluating the safety and efficacy of Yuekangtong extract of ginkgo biloba leaves injection in the treatment of acute primary subjective tinnitus. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
注射治疗:每天或每隔一天深部肌肉注射或缓慢静脉推注(病人平卧)5 mL 本品; 输液治疗:根据病情,通常一日 1~2 次,一次 2~4 支。若必要时可调整剂量至一次 5 支,一日 2 次。给药时可将本品溶于生理盐水、葡萄糖输液, 混合比例为 1:10。若输液为 500 mL,则静滴速度应控制在大约 2~3 小时。后续治疗可以口服银杏叶提取物片剂或滴剂,或遵医嘱。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Injection therapy: Administer 5 mL of this product via deep intramuscular injection or slow intravenous push (with the patient lying flat) daily or every other day. Infusion therapy: Depending on the condition, usually administer 1-2 times daily, with 2-4 ampoules per dose. If necessary, the dosage can be adjusted to 5 ampoules per dose, twice daily. For administration, the product can be dissolved in saline or glucose infusion at a mixing ratio of 1:10. If the infusion volume is 500 mL, the intravenous drip rate should be controlled to approximately 2-3 hours. Subsequent treatment may involve oral administration of Ginkgo biloba extract tablets or drops, or as directed by a physician. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.合并外中耳病变、梅尼埃病、听神经瘤和大前庭水管综合征等病变; 2.合并严重心脏疾病、凝血或血小板功能障碍、有出血倾向、严重肝肾功能不全[谷丙转氨酶(ALT)或谷草转氨酶(AST)> 2.0×正常值上限(ULN),和/或血清肌酐 > 2.0×ULN]、影响其生存的严重疾病者; 3.合并严重精神疾病、严重认知功能障碍等而无法合作或不愿意合作者; 4.对研究中所用药物过敏者或有严重不良反应病史者; 5.妊娠或准备妊娠妇女,哺乳期妇女; 6.研究者认为不适宜参加本临床研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.The subject with External middle ear lesions, Meniere's disease, acoustic neuroma and large vestibular aqueduct syndrome etc; 2.The subject with severe heart disease, coagulation or platelet dysfunction, bleeding tendency, severe liver or kidney dysfunction [ALT or AST > 2.0 ULN, and/or serum creatinine > 2.0 ULN], and serious diseases affecting their survival; 3.The subject with severe mental illness, severe cognitive dysfunction and so on, couldn't or is unwilling to cooperate; 4.The subject is allergic to the study drug or with medical history of serious adverse reaction; 5.Pregnant women, women planning pregnancy or lactating women; 6.The subject who the investigator considers is not suitable to this clinical study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-12-09 00:00:00至 To 2027-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-05-24 00:00:00 至 To 2027-01-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在临床研究电子管理公共平台(Research Manager, ResMan)共享原始数据,链接为:http://www.medresman.org.cn/login.aspx。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Share raw data on the Clinical Research Electronic Management Public Platform (ResMan), linked to: http://www.medresman.org.cn/login.aspx 。 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本次临床试验数据采集通过基于第三方EDC系统的eCRF进行,采用SAS9.4统计软件进行统计分析。EDC系统为北京裕荣医学数据科技有限公司DFdiscover临床试验电子数据采集系统。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The clinical trial data collection was carried out through eCRF based on the third-party EDC system, and SAS9.4 statistical software was used for statistical analysis.The EDC system is the DFdiscover clinical trial electronic data collection system of Beijing Yurong Medical Data Technology Co., Ltd. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |